In the study of congenital hyperinsulinism now enrolling phase III sunRIZE trial

sunrize logo

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Back to Careers